Baxter (BAX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Baxter Declares Quarterly Dividend
July 29, 2015 4:10 PM EDTDEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.
This dividend represents the new quarterly dividend rate for Baxter following its successful spin-off of its biopharmaceuticals business, Baxalta Incorporated, on July 1, 2015. Over its 84-year history, Baxter has consistently paid a dividend to shareholders and followed a disciplined approach to capital allocation that balances reinvestment in the businesses with returning significant value to shareholders.
''This quarterly dividend is... More
Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance
July 29, 2015 4:05 PM EDTCompany Achieves Significant Milestone with Successful Completion of Baxalta Incorporated Spin-Off, Poised for Profitable Growth
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today reported second quarter financial results that exceeded the companys previously issued guidance, and provided its complete financial outlook for the second half of 2015. The results for the second quarter of 2015 include the companys BioScience business, which was officially spun-off on July 1st and is now operating as a publicly traded biopharmaceutical company, Baxalta Incorporated (NYSE: BXLT).... More

